Search filters

Polyneuron extends Series A Financing to CHF 36.5m

Polyneuron Pharmaceuticals AG extended its Series A by CHF 14m bringing the total to CHF 36.5m. Polyneuron is a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients affected by...

Polyphor grants Fosun Pharma license for balixafortide in China

Polyphor AG (SIX: POLN) and Shanghai Fosun Pharmaceutical (Group) Co. Ltd ("Fosun Pharma", stock code: 600196.SH; 02196.HK), through its Swiss affiliate Fosun Pharmaceutical AG entered into an exclusive licensing agreement for...

T3 Pharma closes 25M CHF financing round

T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, closed its third financing round, raising over 25M CHF. The financing was co-led by existing...

Polyphor enters into CHF 19.3 million equity-linked financing arrangement

Polyphor AG has entered into an equity-linked financing arrangement with the French company IRIS to raise a gross amount of up to CHF 19.3 million over a period of two years. Under the financing instrument, IRIS will receive...

Seed-Financing Round with CHF 6 million by Versameb

Versameb AG has closed a CHF 6 million seed financing round. Versameb is engaged in the discovery and development of next-generation RNA-based drugs using its proprietary VERSagile technology platform developing molecules...

Polares Medical closes a USD40M financing for pilot clinical studies

Polares Medical SA, in Lausanne, a clinical stage medical technology company focused on the development of a unique trans-catheter mitral valve hemi-replacement system to treat patients suffering from mitral regurgitation (MR),...

Azafaros expands executive management team and operations

Azafaros B.V., headquartered in Leiden, The Netherlands, has recently incorporated a Swiss subsidiary in the pharma hub of Basel to strengthen its research and development operations. In addition, three experienced industry...

FoRx Therapeutics AG raises EUR 10M Seed-Financing round

FoRx Therapeutics AG, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round led by M...

RLF sells its subsidiary to Sonnet BioTherapeutics Holdings, Inc

RELIEF THERAPEUTICS Holding SA (SIX:RLF; "Relief Holding") announces today the closing of the binding Share Exchange Agreement for the acquisition by Sonnet BioTherapeutics, Inc. ("Sonnet"), now a subsidiary of Sonnet...

NBE-Therapeutics closes USD 22M Series C financing round

NBE-Therapeutics AG closed a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders. The funds will enable NBE to...

You are currently offline. Some pages or content may fail to load.